CNS Pharmaceuticals Files 8-K: Other Events & Financials

Ticker: CNSP · Form: 8-K · Filed: 2025-03-20T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

CNS Pharmaceuticals filed an 8-K today covering other events and financials. Keep an eye out for details.

AI Summary

On March 20, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events. No specific new material events or financial figures were detailed in the provided excerpt.

Why It Matters

This filing signals that CNS Pharmaceuticals is providing updates to the SEC, which could include important operational or financial information relevant to investors.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not contain specific negative or positive material information in the provided excerpt.

Key Players & Entities

FAQ

What specific "Other Events" are being reported by CNS Pharmaceuticals, Inc. in this 8-K filing?

The provided excerpt of the 8-K filing does not detail the specific "Other Events" being reported, only that this item is included in the filing.

What "Financial Statements and Exhibits" are included with this 8-K filing?

The excerpt states that "Financial Statements and Exhibits" are part of the filing, but does not list the specific documents or statements included.

When was the earliest event reported in this Form 8-K?

The earliest event reported in this Form 8-K was on March 20, 2025.

What is the principal executive office address for CNS Pharmaceuticals, Inc.?

The principal executive office address for CNS Pharmaceuticals, Inc. is 2100 West Loop South, Suite 900, Houston, Texas 77027.

Under which state was CNS Pharmaceuticals, Inc. incorporated?

CNS Pharmaceuticals, Inc. was incorporated in Nevada.

From the Filing

0001683168-25-001754.txt : 20250320 0001683168-25-001754.hdr.sgml : 20250320 20250320171522 ACCESSION NUMBER: 0001683168-25-001754 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250320 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250320 DATE AS OF CHANGE: 20250320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001729427 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822318545 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39126 FILM NUMBER: 25757768 BUSINESS ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: 1-800-946-9185 MAIL ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 8-K 1 cns_8k.htm FORM 8-K 8-K false 0001729427 0001729427 2025-03-20 2025-03-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): March 20, 2025 ___________________________   CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ___________________________   Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)   2100 West Loop South , Suite 900 Houston , Texas 77027 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (800) 946-9185   Not Applicable (Former Name or Former Address, if Changed Since Last Report) ___________________________   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbols(s) Name of each exchange on which registered Common stock, par value $0.001 per share CNSP The NASDAQ Stock Market LLC               Item 8.01. Other Events.   As previously reported, on July 26, 2024, CNS Pharmaceuticals, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”). Pursuant to the terms of the Agreement, the Company originally was permitted to sell from time to time through A.G.P., a

View on Read The Filing